Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Abstract

Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gram-negative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.

• Authors: Diego J Maselli, Juan F Fernandez, Christine Y Whong, Kelly Echevarria, Anoop M Nambiar, Antonio Anzueto, Marcos I Restrepo
• Journal: Infection and drug resistance (Infect Drug Resist) Vol. 5 Pg. 43-51 ( 2012) ISSN: 1178-6973 [Electronic] New Zealand
• PMID: 22355258 (Publication Type: Journal Article)